Comparing High-Dose Oral Omeprazole to Standard IV Pantoprazole for Treating Peptic Ulcer Bleeding After Endoscopy

What this Trial Is About

Peptic ulcer bleeding is a leading cause of upper gastrointestinal bleeding worldwide. Researchers are evaluating a high-dose, locally made oral proton pump inhibitor omeprazole compared to the standard intravenous proton pump inhibitor pantoprazole to prevent rebleeding after successful endoscopic treatment. This trial aims to confirm if the oral treatment is not worse than the standard IV treatment in reducing rebleeding and to monitor gastric acid levels over 24 hours. Participants will receive either oral omeprazole at 40 mg twice daily or continuous intravenous pantoprazole at 8 mg per hour, both for 72 hours after endoscopic hemostasis. These two treatment groups are compared in a randomized design to assess their effects on preventing peptic ulcer rebleeding. During the study, patients will be monitored for rebleeding events within 3 and 30 days. Gastric pH will be measured over 24 hours to evaluate acid suppression. The main outcome is the rate of rebleeding within 3 days. The trial includes safety monitoring and follow-up for up to 30 days. Participants clinical status and treatment responses will be carefully recorded throughout the study period.

High Dose Oral Omeprazole in High Risk UGIB